{
    "clinical_study": {
        "@rank": "137974", 
        "arm_group": [
            {
                "arm_group_label": "2.5% East Indian sandalwood oil cream", 
                "arm_group_type": "Active Comparator", 
                "description": "East Indian sandalwood oil in a cream formulation administered twice a day for sixty (60) days"
            }, 
            {
                "arm_group_label": "5% East Indian sandalwood oil cream", 
                "arm_group_type": "Active Comparator", 
                "description": "East Indian sandalwood oil in a cream formulation administered twice a day for sixty (60) days"
            }, 
            {
                "arm_group_label": "10% East Indian sandalwood oil cream", 
                "arm_group_type": "Active Comparator", 
                "description": "East Indian sandalwood oil in a cream formulation administered twice a day for sixty (60) days"
            }, 
            {
                "arm_group_label": "Placebo cream", 
                "arm_group_type": "Placebo Comparator", 
                "description": "A scented cream formulation administered twice a day for sixty (60) days"
            }
        ], 
        "brief_summary": {
            "textblock": "This trial will examine the safety, tolerability and efficacy of three strengths of East\n      Indian sandalwood oil (EISO) in a cream base compared to a placebo for treatment of\n      molluscum contagiosum in pediatric subjects. Trial participants will be asked to apply study\n      medication twice a day for sixty (60) days. Efficacy will be evaluated by clinical staff and\n      patients will be asked to assess tolerability as well as any improvement experienced during\n      the trial."
        }, 
        "brief_title": "A Dose Range-Finding Phase 2 Trial of a Botanical Drug for the Treatment of Molluscum Contagiosum in Pediatric Subjects", 
        "completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Molluscum Contagiosum", 
        "condition_browse": {
            "mesh_term": "Molluscum Contagiosum"
        }, 
        "detailed_description": {
            "textblock": "This trial will be a multi-center, double-blind, randomized, placebo-controlled safety and\n      efficacy trial to evaluate the efficacy and safety of VIR003 treatment regimen when\n      administered to pediatric subjects with molluscum contagiosum.\n\n      Once subject eligibility is confirmed the subject will start the Treatment Period of the\n      study.  All subjects will receive one of three active treatments or placebo with the first\n      dose applied at the Day 0 Study Visit.  Subjects will be instructed on how to apply the\n      study medication twice a day for 60 days of treatment.  Subjects will return to the clinic\n      on Study Days, 7, 14, 30, 45, and 60 for routine evaluations and then on Study Day 90 for\n      the Final Study Visit.\n\n      The study will be monitored by a data safety monitoring board (DSMB) comprised of a medical\n      monitor, dermatologist and statistician.  The purpose of the DSMB will be to monitor the\n      emergence of adverse events (AEs) and serious adverse events (SAEs) at periodic intervals\n      throughout the enrollment and treatment phases of the study"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Subjects will be included in the trial if they meet all of the following criteria:\n\n          -  Are between 2 and 18 years of age, at Screening.\n\n          -  Have a diagnosis of molluscum contagiosum that is treatable with a topical agent.\n\n          -  Are free of any systemic or dermatologic disorder, which, in the opinion of the\n             investigator will interfere with the study results or increase the risk of adverse\n             events.\n\n          -  Are willing to refrain from using non-approved lotions, sunscreen, moisturizer,\n             cleansers, cosmetics or creams on the affected areas during the treatment period.\n\n          -  Whose parent or guardian is able to give written informed consent in a manner\n             approved by the Institutional Review Board and comply with the requirements of the\n             study.\n\n        Exclusion Criteria:\n\n        Subjects will be excluded from the trial if they meet any of the following criteria:\n\n          -  Are immunosuppressed.\n\n          -  Have used or are planning to use immunosuppressive or immunomodulatory medication\n             (including oral or parenteral corticosteroids) in the previous 30 days.\n\n          -  Are undergoing treatment or have been treated in the last 30 days prior to Screening\n             with isotretinoin or any other type of topical therapy (e.g., corticosteroids,\n             cantharidin, podophyllin, podofilox, iodine, salicylic acid, retinoids, diclofenac,\n             hyaluronic acid, potassium hydroxide, imiquimod).\n\n          -  Have used liquid nitrogen in the treatment area in the last 30 days prior to\n             Screening.\n\n          -  Have undergone curettage, electrocoagulation, taping or clamping of the infected\n             area.\n\n          -  Are taking antiviral medication including but not limited to cimetidine and\n             cidofovir.\n\n          -  Have any active skin malignancy or infection.\n\n          -  Have a molluscum contagiosum infection in an untreatable area (i.e., periorbital,\n             urogenital, etc.).\n\n          -  Have any condition that in the opinion of the investigator would confound the safety\n             and/or efficacy assessments.\n\n          -  Have participated in any clinical trial in the previous 30 days.\n\n          -  Have a known sensitivity to any of the constituents of the test product including\n             sensitivities to sandalwood oil, fragrances or any member of the Compositae family of\n             vascular plants (e.g., sunflowers, daisies, dahlias, etc.).\n\n          -  Are pregnant, breastfeeding, or unwilling to practice an acceptable form of birth\n             control during the study, if applicable.\n\n          -  Have a present condition or abnormality that in the opinion of the Investigator would\n             compromise the safety of the subject or the quality of the data"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "18 Years", 
            "minimum_age": "2 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02024581", 
            "org_study_id": "VIR003-01"
        }, 
        "intervention": [
            {
                "arm_group_label": "2.5% East Indian sandalwood oil cream", 
                "intervention_name": "2.5% East Indian sandalwood oil cream", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Albuterpenoids", 
                    "EISO"
                ]
            }, 
            {
                "arm_group_label": "5% East Indian sandalwood oil cream", 
                "intervention_name": "5% East Indian sandalwood oil cream", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Albuterpenoids", 
                    "EISO"
                ]
            }, 
            {
                "arm_group_label": "10% East Indian sandalwood oil cream", 
                "intervention_name": "10% East Indian sandalwood oil cream", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Albuterpenoids", 
                    "EISO"
                ]
            }, 
            {
                "arm_group_label": "Placebo cream", 
                "description": "A scented cream matching the appearance of the active comparator creams", 
                "intervention_name": "Placebo Cream", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "pediatric", 
            "dermatology", 
            "East Indian sandalwood oil", 
            "pox virus"
        ], 
        "lastchanged_date": "December 26, 2013", 
        "location": {
            "contact": {
                "email": "vcozad@texasdls.com", 
                "last_name": "Valerie A. Cozad, CRC", 
                "phone": "210-829-5180", 
                "phone_ext": "308"
            }, 
            "facility": {
                "address": {
                    "city": "San Antonio", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "78218"
                }, 
                "name": "Texas Dermatology and Laser Specialists"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Safety and Efficacy Trial of VIR003 at Three Dose Levels for the Treatment of Molluscum Contagiosum in Pediatric Subjects", 
        "other_outcome": {
            "description": "Tolerability will be assessed on a scale of 0 to 3 for itching, scaling, burning dryness and stinging.  The number and percentage of subjects reporting burning, itching, scaling, erythema, dryness or stinging (Grade 1 or higher) will be tabulated by severity.", 
            "measure": "Tolerability of treatment", 
            "safety_issue": "No", 
            "time_frame": "Subjects will answer treatment tolerability questions at each visit during the treatment period (Visit 2 (Day 7), Visit 3 (Day 14), Visit 4 (Day 30), Visit 5 (Day 45) and Visit 6 (Day 60))"
        }, 
        "overall_contact": {
            "email": "drbrowning@texasdls.com", 
            "last_name": "John C. Browning, MD FAAD FAAP", 
            "phone": "(210) 829-5180"
        }, 
        "overall_official": {
            "affiliation": "Texas Dermatology and Laser Specialists", 
            "last_name": "John C. Browning, MD FAAD FAAP", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The preliminary efficacy evaluation for the study will be the complete resolution of lesion following 60 days of treatment and assessed at Study Day 60.", 
            "measure": "Complete resolution of lesions", 
            "safety_issue": "No", 
            "time_frame": "Outcome measured after 60 days of treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02024581"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Percent change in lesion count from Baseline to Study Day 60 in evaluable subjects", 
                "measure": "Change in lesion count", 
                "safety_issue": "No", 
                "time_frame": "Measured following 60 days of treatment"
            }, 
            {
                "description": "Percentage of subjects who are very much improved, much improved, or improved (treatment success) at Day 60, as judged by the Global Aesthetic Improvement Scale (GAIS).", 
                "measure": "Improvement in GAIS score", 
                "safety_issue": "No", 
                "time_frame": "Measured following 60 days of treatment"
            }, 
            {
                "description": "The primary purpose of this study is to determine the safety profile of VIR003 at 3 dose concentration.\nSafety will be assessed by evaluating adverse events (AEs) with respect to severity, duration, and relationship to study drug compared to placebo.\nIn addition the following cutaneous safety evaluations will be performed at each study visit.\nScaling on a scale of 0 to 3.\nErythema on a scale of 0 to 3", 
                "measure": "Safety profile of the treatment", 
                "safety_issue": "Yes", 
                "time_frame": "Subjects will be queried for adverse events at each visit during the treatment period (Visit 2 (Day 7), Visit 3 (Day 14), Visit 4 (Day 30), Visit 5 (Day 45) and Visit 6 (Day 60))"
            }
        ], 
        "source": "ViroXis Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "ViroXis Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}